AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca announced a joint development and commercialization partnership with HUTCHMED, a company based in China with operations in Shanghai.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cavendish acted as broker for Hutchmed trials combining Savolitinib with AstraZeneca's Tagrisso.Sub-event
- AstraZeneca paid a milestone payment to Hutchison MediPharma Limited on August 7, 2025.Sub-event
AstraZeneca partnered with HUTCHMED (China) for joint development and commercialization of ORPATHYS®.1 source
Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireHUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China HONG KONG and SHANGHAI and FLO